BRAF and neoplasm: However, the efficacy of targeted agents varies widely based on the tumor type; e.g., the combination of BRAF and MEK inhibitors is known to be highly effective in melanoma patients with BRAFV600 mutations, while it has limited efficacy in colorectal cancer patients [37].